[ad_1]
It was announced that the coronavirus vaccine developed jointly by Oxford and AstraZeneca was 70% effective in protecting against the virus.
According to Reuters news, AstraZeneca announced that the new coronavirus vaccine developed with the University of Oxford showed an average efficiency of 70% in protecting against the virus in two study segments.
British Health Minister Matt Hancock commented on the Oxford vaccine as great news shown by the data.
“We have 100 million doses. Most of the distribution will take place in the new year,” said Minister Hancock.
“IT HAS GENERATED A STRONG IMMUNE RESPONSE IN THE ELDERLY”
It was reported that the candidate vaccine developed in collaboration with AstraZeneca, the pharmaceutical company at the University of Oxford in England, against the new type of coronavirus (Covid-19), created a strong immune response in the elderly in phase 2 studies.
“A STRONG IMMUNITY HAS BEEN DEVELOPED ON THOSE AT RISK OF DEATH OR SERIOUS DISEASE”
In the article published in the Lancet medical journal on the candidate Covid-19 vaccine developed by AstraZeneca in collaboration with the University of Oxford, the results of the second phase trials administered two doses of vaccine or a placebo to approximately 560 healthy adult volunteers were shared. . In the first and second trials of the vaccine, it was claimed that it has developed strong immunity in groups at risk of death or serious illness due to Covid-19.
NO SIDE EFFECTS ARE SPECIFIED
In the second phase of the studies, it was noted that the vaccine showed similar antibody and T-cell responses in all volunteers in 3 different age groups, 18-55, 56-69, 70 and above, and the volunteers did not report any collateral effect.
Oxford Vaccine Group researcher Dr. Maheshi Ramasamy said he was delighted to see the vaccine give similar immune responses not only in the elderly but also in the young.
TESTS ON VACCINES ARE DISCONTINUED IN THE USA
At the beginning of September, AstraZeneca’s 2nd phase vaccination trials with the University of Oxford against the virus were suspended in the US due to a neurological problem in one of the subjects, but it was announced that AstraZeneca would continue. his studies after it was decided that the problem was not caused by the Covid-19 vaccine.
YOU CAN ALSO SEE
Source link
